By Billy Candra 
Cambridge researchers have unveiled groundbreaking findings demonstrating that bilateral salpingo-oophorectomy (BSO)—the surgical removal of the ovaries and fallopian tubes—is associated with a substantial reduction in the risk of early death among women with breast cancer who carry particular BRCA1 and BRCA2 genetic variants. Published today in The Lancet Oncology, this pivotal study provides much-needed clarity on the long-term benefits of BSO, addressing long-standing concerns about potential unintended consequences, particularly for those with a prior history of breast cancer. Crucially, the research found no evidence of increased risk for serious long-term adverse outcomes such as heart disease, stroke, or depression, offering significant reassurance to both patients and clinicians.
Understanding the Genetic Imperative: BRCA1 and BRCA2
The human genome is a vast instruction manual, and within it, certain genes play critical roles in maintaining cellular health. Among the most well-known are BRCA1 and BRCA2 (BReast CAncer genes 1 and 2). These are tumor suppressor genes, meaning they are normally responsible for repairing damaged DNA and preventing uncontrolled cell growth. When these genes harbor pathogenic variants (often referred to as mutations), their ability to perform this vital repair function is compromised. This dramatically increases an individual’s lifetime risk of developing certain cancers, most notably breast and ovarian cancer.
The discovery of BRCA1 in 1990 and BRCA2 in 1994 revolutionized our understanding of hereditary cancer syndromes. Prior to this, familial patterns of cancer were recognized, but the specific genetic links remained elusive. Today, it is estimated that approximately 1 in 300 to 1 in 800 people in the general population carry a pathogenic variant in either BRCA1 or BRCA2. However, this prevalence can be significantly higher in certain ethnic groups, such as Ashkenazi Jewish individuals, where it is estimated that 1 in 40 individuals carry a BRCA founder mutation.
For women carrying these variants, the lifetime risk of developing breast cancer can range from 40% to 85%, significantly higher than the average lifetime risk of around 13% for women in the general population. The risk of ovarian cancer is also starkly elevated, ranging from 15% to 60%, compared to less than 2% in the general population. Ovarian cancer, in particular, is often diagnosed at advanced stages due to its non-specific symptoms, making effective early prevention strategies like BSO incredibly vital. Given the aggressive nature of some BRCA-associated cancers and the lack of reliable early detection methods for ovarian cancer, prophylactic surgeries have become cornerstone recommendations in the management of these high-risk individuals.
Bilateral Salpingo-Oophorectomy: A Prophylactic Strategy
Bilateral salpingo-oophorectomy (BSO) involves the surgical removal of both ovaries and fallopian tubes. For women with BRCA1 and BRCA2 pathogenic variants, this procedure is not performed to treat an existing cancer but rather to prevent future cancers from developing. The fallopian tubes are removed because recent research indicates that many ovarian cancers, especially the high-grade serous type, may originate in the fimbriae (finger-like projections) at the ends of the fallopian tubes.
Current clinical guidelines recommend BSO at specific age ranges to balance the benefits of risk reduction with potential impacts on quality of life. For BRCA1 carriers, BSO is typically recommended between the ages of 35 and 40 years, while for BRCA2 carriers, it is recommended between 40 and 45 years. These age windows are chosen because the risk of ovarian cancer significantly increases after these ages, but performing the surgery too early can lead to a prolonged period of surgically induced menopause, with its associated health challenges.
Previous studies have robustly demonstrated BSO’s efficacy in preventing ovarian cancer, showing an approximate 80% reduction in risk for BRCA1/2 carriers. However, the procedure inherently induces early menopause, leading to an abrupt cessation of ovarian hormone production, primarily estrogen. This can trigger a range of symptoms, including hot flashes, night sweats, vaginal dryness, sleep disturbances, and mood changes. More importantly, the long-term absence of estrogen has been linked to potential health concerns such as increased risk of cardiovascular disease, osteoporosis, and cognitive decline in the general population.
For women with a prior history of breast cancer, the situation is particularly complex. Many breast cancers are hormone-receptor positive, meaning their growth is fueled by estrogen. Consequently, these patients are often advised against or are unable to receive hormone replacement therapy (HRT) to mitigate menopausal symptoms, as HRT could potentially stimulate a recurrence of their breast cancer. This leaves a significant population of women facing the benefits of cancer prevention through BSO, yet without the customary support to manage the challenging side effects of early menopause. This uncertainty regarding the overall impact of BSO on long-term survival and quality of life for BRCA1/2 carriers with breast cancer underscored the critical need for the new Cambridge study.
Navigating the Ethical Imperative: An Innovative Research Approach
Traditionally, the "gold standard" for evaluating medical interventions is the randomized controlled trial (RCT). In an RCT, participants are randomly assigned to either receive the intervention (e.g., BSO) or a control (e.g., no BSO), allowing researchers to isolate the intervention’s effects. However, for a procedure like BSO in high-risk BRCA1/2 carriers, conducting an RCT would be ethically untenable. Randomly assigning women with a profoundly elevated risk of a deadly cancer to a control group, thereby denying them a proven risk-reducing surgery, would expose them to substantially greater harm.
To overcome this ethical barrier, a pioneering team at the University of Cambridge, in collaboration with the National Disease Registration Service (NDRS) in NHS England, employed an innovative observational approach. They leveraged the vast repositories of electronic health records and genetic testing laboratory data collected and curated by the NDRS. This allowed them to retrospectively examine the long-term outcomes of BSO among a large cohort of BRCA1 and BRCA2 pathogenic variant carriers who had already been diagnosed with breast cancer. This methodology represents a powerful application of real-world data to address critical clinical questions that would otherwise be impossible to answer.
The study identified a total of 3,400 women in the UK carrying a cancer-causing variant in either BRCA1 or BRCA2 (approximately 1,700 women for each gene). Among this cohort, around 850 of the BRCA1 carriers and 1,000 of the BRCA2 carriers had undergone BSO surgery during the study’s follow-up period. The median follow-up time for the study was 5.5 years, providing sufficient duration to assess significant long-term health outcomes. The researchers meticulously analyzed various endpoints, including overall mortality, incidence of second cancers, and the occurrence of conditions typically associated with estrogen deficiency.
Groundbreaking Findings: Survival Benefits and Reassurance
The results of the Cambridge study are profoundly impactful. The primary finding was a substantial reduction in the risk of early death from any cause among women who underwent BSO. Specifically, women who had BSO were approximately half as likely to die from cancer or any other cause during the follow-up period compared to those who did not undergo the procedure.
Breaking down this overall mortality benefit, the study revealed nuanced differences between the two gene variants:
- BRCA2 carriers who underwent BSO experienced a 56% reduction in early death risk.
- BRCA1 carriers who underwent BSO saw a 38% reduction in early death risk.
While both reductions are significant, the greater benefit observed in BRCA2 carriers warrants further investigation, potentially reflecting differences in cancer spectrum or hormone sensitivity between the two genotypes.
Beyond overall survival, the study also demonstrated a tangible benefit in preventing subsequent cancers. Women who underwent BSO were found to be at approximately a 40% lower risk of developing a second primary cancer. This finding is particularly important for BRCA1/2 carriers, who face an elevated risk of multiple primary cancers throughout their lives, including contralateral breast cancer (cancer in the other breast) and other BRCA-associated malignancies.
Perhaps equally significant, and highly reassuring, were the study’s findings regarding potential adverse long-term outcomes. Contrary to widespread concerns and some previous studies in the general population, the Cambridge researchers found no link between BSO and an increased risk of heart disease, stroke, or depression in this specific high-risk cohort. This is a critical piece of information, as it directly addresses the anxieties surrounding the potential negative health consequences of surgically induced early menopause, especially in women who cannot use HRT.
While the observational nature of the study means that researchers cannot claim with 100% certainty that BSO causes this reduction in risk, the robust evidence, careful statistical adjustments for confounding factors, and consistency with biological plausibility (e.g., reduction of estrogen-driven cancers) strongly point towards a causal relationship.
Hend Hassan, a PhD student at the Centre for Cancer Genetic Epidemiology and first author of the study, articulated the profound implications: "We know that removing the ovaries and fallopian tubes dramatically reduces the risk of ovarian cancer, but there’s been a question mark over the potential unintended consequences that might arise from the sudden onset of menopause that this causes. Reassuringly, our research has shown that for women with a personal history of breast cancer, this procedure brings clear benefits in terms of survival and a lower risk of other cancers without the adverse side effects such as heart conditions or depression."
Addressing Disparities in Access and Uptake
Despite the clear benefits, the study also brought to light concerning disparities in the uptake of BSO among different demographic groups. The data indicated that most women undergoing BSO were white. Black and Asian women were found to be approximately half as likely to have BSO compared to white women. Furthermore, women residing in less deprived areas were more likely to undergo the procedure compared to those in the most-deprived categories.
These findings highlight critical issues of health equity and access to preventative care. Such disparities can stem from a complex interplay of factors, including:
- Awareness and Education: Lower awareness of BRCA testing and BSO recommendations among certain ethnic minority groups or in socioeconomically disadvantaged communities.
- Access to Genetic Counseling and Services: Barriers to accessing genetic testing and subsequent counseling, which are crucial for informed decision-making regarding prophylactic surgeries.
- Cultural and Linguistic Barriers: Communication challenges, cultural beliefs, or differing perceptions of surgery and risk among diverse populations.
- Socioeconomic Factors: Financial constraints, time off work, childcare issues, or lack of transportation impacting the ability to attend appointments or undergo surgery.
- Healthcare Provider Bias: Unconscious biases or systemic inequalities within the healthcare system that may lead to differential recommendations or access to care.
Hassan underscored the urgency of addressing these inequities: "Given the clear benefits that this procedure provides for at-risk women, it’s concerning that some groups of women are less likely to undergo it. We need to understand why this is and encourage uptake among these women." This calls for targeted public health initiatives, culturally sensitive genetic counseling services, and proactive outreach to ensure equitable access to life-saving preventative measures.
Implications for Clinical Practice and Future Directions
The findings of this Cambridge study are set to significantly influence clinical guidance and patient counseling. Professor Antonis Antoniou, from the Department of Public Health and Primary Care and the study’s senior author, emphasized this point: "Our findings will be crucial for counselling women with cancer linked to one of the BRCA1 and BRCA2 variants, allowing them to make informed decisions about whether or not to opt for this operation."
For genetic counselors, oncologists, surgeons, and primary care physicians, this research provides robust, real-world evidence to confidently discuss the comprehensive benefits of BSO with their BRCA1/2-positive breast cancer patients. It allows for a more nuanced conversation, emphasizing not only ovarian cancer prevention but also improved overall survival and a reduced risk of second cancers, all without the previously feared long-term side effects on cardiovascular or mental health.
The study also serves as a powerful testament to the value of large-scale, integrated health datasets. Professor Antoniou, who is also Director of the Cancer Data-Driven Detection programme, noted: "The study also highlights the power of exceptional NHS datasets in driving impactful, clinically relevant research." This collaborative model, leveraging anonymized patient data, represents a future pathway for medical research, especially when traditional RCTs are not feasible.
Looking ahead, while the current study provides significant clarity, ongoing research will remain vital. This includes:
- Longer-term follow-up: To confirm the durability of these benefits beyond the 5.5-year median follow-up.
- Quality of life studies: To further explore the patient experience following BSO, including specific menopausal symptoms and their management, especially for those unable to use HRT.
- Mechanistic studies: To better understand the biological pathways through which BSO confers its survival benefits and reduces the risk of second cancers.
- Intervention studies: To develop and test strategies for improving equitable access to genetic testing and prophylactic surgeries across diverse populations.
This research, funded by Cancer Research UK with additional support from the National Institute for Health and Care Research (NIHR) Cambridge Biomedical Research Centre, represents a significant stride in personalized cancer prevention and management. It underscores the importance of a holistic approach to care for individuals with inherited cancer risks, combining cutting-edge genetic insights with evidence-based surgical interventions. The ongoing efforts, such as the fundraising for the new Cambridge Cancer Research Hospital, highlight a continued commitment to advancing cancer diagnosis, treatment, and prevention, promising to impact the lives of countless patients across the UK and globally. By providing definitive answers to critical questions, this study empowers women with BRCA1 and BRCA2 pathogenic variants to make truly informed decisions about their health, offering a clearer path towards longer, healthier lives.
